Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04017546 · ClinicalTrials.gov registry record · Phase 1
CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory AML or MDS
A Phase 1 study of AML and MDS, sponsored by Cyclacel Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
- 1
- Study location
NCT04017546 is a Phase 1 study of AML and MDS that has completed, run by Cyclacel Pharmaceuticals. The registered enrollment target is 14 participants, below the 133-participant average among 29 other AML trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04017546, a Phase 1 study of AML and MDS, has completed, sponsored by Cyclacel Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
- 1
- Study location
Study Summary
A Phase I Combination Study of CYC065 and Venetoclax for Relapsed or Refractory AML or MDS
Interventions
- DRUG Venetoclax
- DRUG CYC065
Study Locations (1)
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2019-08-02 |
| Est. Completion | 2023-04-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04017546
The ClinicalTrials.gov registry entry for NCT04017546 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 133-participant average among 29 other AML trials with a reported enrollment target (89% lower). The listed sponsor is Cyclacel Pharmaceuticals, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with AML appearing as the primary indexed condition, and to 2 interventions - of which Venetoclax is the first listed.
NCT04017546 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT04017546 about?
NCT04017546 is a clinical study titled "CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory AML or MDS". A Phase I Combination Study of CYC065 and Venetoclax for Relapsed or Refractory AML or MDS
What is the current status of trial NCT04017546?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2019-08-02. Estimated completion is 2023-04-05.
What conditions does trial NCT04017546 study?
This clinical trial studies the following conditions: AML, MDS.
What interventions are being tested in trial NCT04017546?
The interventions under investigation include: Venetoclax (DRUG), CYC065 (DRUG).
Who is sponsoring clinical trial NCT04017546?
This trial is sponsored by Cyclacel Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04017546 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for AML
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Revumenib in Combination With 7+3 + Midostaurin in AML
RECRUITING · Phase 1
-
UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy
RECRUITING · Phase 1
-
A Study of TSC-100 and TSC-101 in AML, ALL and MDS in Patients Undergoing Allogeneic Peripheral Blood Stem Transplantation
RECRUITING · Phase 1
-
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
RECRUITING · Phase 1
-
CC-486 and Venetoclax for Acute Myeloid Leukemia
RECRUITING · Phase 1
-
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.